View Older Stories View More Recent Stories
-
Edwards Lifesciences (EW) Tops Q2 EPS by 5c; offers guidance
-
FDA: Edwards Lifesciences (EW) is recalling arterial cannula due to risk of wire exposure
-
Edwards Lifesciences (EW) Files Mixed Shelf
-
Nephron Upgrades Edwards Lifesciences (EW) to Buy
-
Argus Starts Edwards Lifesciences (EW) at Buy
-
Canaccord Genuity Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Citi Reiterates 'Top Pick' on Boston Scientific (BSX)
-
Edwards Lifesciences (EW) gains after Boston Scientific (BSX) ends worldwide sales of the ACURATE neo2 and ACURATE Prime
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Edwards Lifesciences (EW) Added as Top Pick at Citi, PODD Removed
-
Edwards Lifesciences (EW) PT Raised to $83 at Piper Sandler
-
Edwards Lifesciences (EW) TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Piper Sandler Upgrades Edwards Lifesciences (EW) to Overweight
-
Edwards Lifesciences (EW) Tops Q1 EPS by 4c, Offers Guidance
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) PT Raised to $71 at Canaccord Genuity
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
-
Stifel Upgrades Edwards Lifesciences (EW) to Buy
-
Wolfe Research Downgrades Edwards Lifesciences (EW) to Underperform
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of Edwards Lifesciences Corporation (EW)
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
BofA Securities Upgrades Edwards Lifesciences (EW) to Buy
-
EW DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action - EW
-
Faruqi & Faruqi Reminds Edwards Lifesciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW
-
EW DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors with Losses in Excess of $100k to Secure Counsel Before Important December 13 Deadline in Securit
-
Edwards Lifesciences (EW) PT Raised to $75 at TD Cowen as '25 Outlook Meets Expectations'
-
Bernstein SocGen Group Reiterates Market Perform Rating on Edwards Lifesciences (EW), 'Bullish Investor Day'
-
RBC Sees 'Multi-Year Growth Runway' for Edwards Lifesciences (EW); PT Raised
-
Edwards Lifesciences (EW) PT Raised to $78 at Truist Securities
-
Edwards Lifesciences (EW) PT Raised to $68 at Canaccord Genuity
-
Oppenheimer Reiterates Outperform Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Outlines Growth Strategy
-
RBC comments on medical devices sector ahead of EW's Investor Day
-
Piper Sandler Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Citi Removes Two names from 90-Day Catalyst Watch Lists
-
Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
-
BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
-
TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)
